Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Denosumab
•
Bisphosphonate
•
Endocrinology
•
Primary Care
In a patient with history of atypical femoral fracture while on denosumab how do you sequence further treatment options?
Related Questions
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
Would you consider PTH analogue in a patient with mildly elevated PTH?
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
How do you approach management of osteoporosis in patients post lung transplant?
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
